Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Ranibizumab: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 12:34, 6 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460148751 of page Ranibizumab for the Chem/Drugbox validation project (updated: 'ChEMBL', 'KEGG').  Latest revision as of 20:52, 10 December 2024 edit 2600:8800:311b:4100:786d:49db:b20f:1c05 (talk) →Pharmacology: MoS 
Line 1: Line 1:
{{Short description|Pharmaceutical drug}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Use dmy dates|date=July 2024}}
{{Drugbox
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458438803
| verifiedrevid = 464380069

<!--Monoclonal antibody data-->
| type = mab | type = mab
| image =
| width =
| alt =
| caption =

<!-- Monoclonal antibody data -->
| mab_type = Fab | mab_type = Fab
| source = zu/o | source = zu/o
| target = ] | target = ] (VEGF-A)


<!--Clinical data--> <!-- Clinical data -->
| pronounce =
| tradename = Lucentis
| tradename = Lucentis, others
| Drugs.com = {{drugs.com|monograph|ranibizumab}} | Drugs.com = {{drugs.com|monograph|ranibizumab}}
| MedlinePlus = a607044 | MedlinePlus = a607044
| DailyMedID = Ranibizumab
| licence_EU = Lucentis
| pregnancy_AU = D
| licence_US = Ranibizumab
| pregnancy_AU_comment = <ref name="AusPAR: Ranibizumab" /><ref name="Byooviz APMDS">{{cite web | title=Byooviz APMDS | website=Therapeutic Goods Administration (TGA) | date=6 September 2022 | url=https://www.tga.gov.au/resources/auspmd/byooviz | access-date=7 March 2024}}</ref>
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category=
| pregnancy_US = C
| routes_of_administration = ]
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| class =
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| ATC_prefix = S01
| ATC_suffix = LA04
| ATC_supplemental =
| biosimilars = Byooviz,<ref name="Byooviz FDA label" /><ref name="Byooviz EPAR" /> Cimerli,<ref name="Cimerli FDA label" /> Ranivisio,<ref name="Ranivisio EPAR" /> Raniviz,<ref name="Raniviz APMDS" /> Ranopto, Rimmyrah,<ref name="Rimmyrah EPAR" /> Susvimo,<ref name="Susvimo FDA label" /> Ximluci<ref name="Ximluci EPAR" /> ranibizumab-eqrn,<ref name="Cimerli FDA label" /> ranibizumab-nuna<ref name="Byooviz FDA label" />

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = <ref name="AusPAR: Ranibizumab">{{cite web | title=AusPAR: Ranibizumab | website=Therapeutic Goods Administration (TGA) | date=9 December 2014 | url=https://www.tga.gov.au/auspar/auspar-ranibizumab-1 | access-date=20 September 2021 | archive-date=21 September 2021 | archive-url=https://web.archive.org/web/20210921062654/https://www.tga.gov.au/auspar/auspar-ranibizumab-1 | url-status=live }}</ref><ref name="Byooviz APMDS" /><ref name="Raniviz APMDS">{{cite web | title=Raniviz APMDS | website=Therapeutic Goods Administration (TGA) | date=8 January 2024 | url=https://www.tga.gov.au/resources/auspmd/raniviz | access-date=7 March 2024 | archive-date=8 February 2024 | archive-url=https://web.archive.org/web/20240208091930/https://www.tga.gov.au/resources/auspmd/raniviz | url-status=live }}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = /{{nbsp}}Schedule D<ref>{{cite web | title=Summary Basis of Decision - Byooviz | website=Health Canada | date=12 August 2022 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00598&lang=en | access-date=29 September 2022 | archive-date=29 September 2022 | archive-url=https://web.archive.org/web/20220929042223/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00598&lang=en | url-status=live }}</ref><ref>{{cite web | title=Summary Basis of Decision for Ranopto | website=Drug and Health Products Portal | date=1 September 2012 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1717516069966 | access-date=23 July 2024}}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM | legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only | legal_US = Rx-only
| legal_US_comment = <ref name="Lucentis FDA label">{{cite web | title=Lucentis- ranibizumab injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d | access-date=20 September 2021 | archive-date=21 September 2021 | archive-url=https://web.archive.org/web/20210921055712/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d | url-status=live }}</ref><ref name="Byooviz FDA label">{{cite web | title=Byooviz Nuna- ranibizumab injection, solution | website=DailyMed | date=27 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e46db299-edd1-4457-89b2-c1e2e505f1b0 | access-date=2 August 2022 | archive-date=3 August 2022 | archive-url=https://web.archive.org/web/20220803044308/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e46db299-edd1-4457-89b2-c1e2e505f1b0 | url-status=live }}</ref><ref name="Susvimo FDA label">{{cite web | title=Susvimo- ranibizumab injection, solution | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c6d9e2a-9a77-4d11-b692-de87cfde3444 | access-date=19 December 2021 | archive-date=19 December 2021 | archive-url=https://web.archive.org/web/20211219214639/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c6d9e2a-9a77-4d11-b692-de87cfde3444 | url-status=live }}</ref><ref name="Cimerli FDA label">{{cite web | title=Cimerli- ranibizumab-eqrn injection, solution | website=DailyMed | date=19 October 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c | access-date=21 January 2023 | archive-date=21 January 2023 | archive-url=https://web.archive.org/web/20230121062629/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c | url-status=live }}</ref>
| routes_of_administration = Intravitreal injection
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Lucentis EPAR">{{cite web | title=Lucentis EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis | access-date=9 September 2021 | archive-date=10 September 2021 | archive-url=https://web.archive.org/web/20210910053245/https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name="Byooviz EPAR">{{cite web | title=Byooviz EPAR | website=European Medicines Agency | date=23 June 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/byooviz | access-date=9 September 2021 | archive-date=10 September 2021 | archive-url=https://web.archive.org/web/20210910053259/https://www.ema.europa.eu/en/medicines/human/EPAR/byooviz | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name="Ranivisio EPAR" /><ref name="Ximluci EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = <!-- For countries not listed above -->


<!--Pharmacokinetic data--> <!-- Pharmacokinetic data -->
| bioavailability =
| elimination_half-life = Approx. 9 days<ref>. Genentech. June 2010.</ref>
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life = Approx. 9 days<ref name="Lucentis FDA label" />
| duration_of_action =
| excretion =


<!--Identifiers--> <!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 347396-82-1 | CAS_number = 347396-82-1
| CAS_supplemental =
| ATC_prefix = S01
| ATC_suffix = LA04 | PubChem =
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01270 | DrugBank = DB01270
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ZL1R02VT79 | UNII = ZL1R02VT79
| KEGG_Ref = {{keggcite|changed|kegg}} | KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = <!-- blanked - oldvalue: D05697 --> | KEGG = D05697
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1201825 --> | ChEMBL = 1201825
| NIAID_ChemDB =
| C=2158 | H=3282 | N=562 | O=681 | S=12
| PDB_ligand =
| molecular_weight = 48000dalton
| synonyms =

<!-- Chemical and physical data -->
| C=2158 | H=3282 | N=562 | O=681 | S=12
}} }}

'''Ranibizumab''', sold under the brand name '''Lucentis''' among others, is a ] fragment (]) created from the same parent mouse antibody as ]. It is an ]<ref>{{cite journal | vauthors = Heidary F, Hitam WH, Ngah NF, George TM, Hashim H, Shatriah I | title = Intravitreal Ranibizumab for Choroidal Neovascularization in Best's Vitelliform Macular Dystrophy in a 6-Year-Old Boy | journal = Journal of Pediatric Ophthalmology and Strabismus | volume = 48 Online | issue = 6 | pages = e19–e22 | date = March 2011 | pmid = 21417187 | doi = 10.3928/01913913-20110308-02 | url = https://journals.healio.com/doi/abs/10.3928/01913913-20110308-02 | access-date = 1 October 2021 | url-status = live | archive-url = https://web.archive.org/web/20211001185206/https://journals.healio.com/doi/abs/10.3928/01913913-20110308-02 | archive-date = 1 October 2021 }}</ref> that is approved to treat the "wet" type of age-related ] (AMD, also ARMD), ], and ] due to ] or ].

Ranibizumab was developed by ] and marketed by them in the United States, and elsewhere by ],<ref name="Lucentis Fact Sheet">{{cite web | title=Lucentis Fact Sheet | website=Genentech | url=https://www.gene.com/gene/products/information/tgr/lucentis/factsheet.html | access-date=28 October 2012 | archive-url=https://web.archive.org/web/20121028214234/http://www.gene.com/gene/products/information/tgr/lucentis/factsheet.html | archive-date=28 October 2012 }}</ref> under the brand name Lucentis.<ref name="Lucentis FDA label" /><ref name="Lucentis Fact Sheet" /><ref name="Lucentis Drug Approval Package" /> Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006,<ref name="Lucentis Drug Approval Package">{{cite web | title=Drug Approval Package: Lucentis (Ranibizumab) NDA #125156 | website=U.S. ] (FDA) | date=26 September 2006 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_LucentisTOC.cfm | access-date=2 August 2022 | archive-date=2 August 2022 | archive-url=https://web.archive.org/web/20220802102442/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_LucentisTOC.cfm | url-status=live }}</ref><ref name="Lucentis FDA label" /> and in the European Union in January 2007.

==Medical uses==
In the United States, ranibizumab is ] for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.<ref name="Lucentis FDA label" /><ref name="FDA PR 20210920" />

In the European Union, ranibizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion, and visual impairment due to choroidal neovascularisation.<ref name="Lucentis EPAR" /><ref name="Byooviz EPAR" /><ref name="Ranivisio EPAR" />

It is used for ].<ref>{{cite journal | vauthors = Ramin S, Soheilian M, Habibi G, Ghazavi R, Gharebaghi R, Heidary F | title = Age-Related Macular Degeneration: A Scientometric Analysis | journal = Medical Hypothesis, Discovery & Innovation in Ophthalmology | volume = 4 | issue = 2 | pages = 39–49 | date = 2015 | pmid = 26060829 | pmc = 4458325 }}</ref> Its effectiveness is similar to that of ]<ref name="For2014" /><ref>{{cite journal | vauthors = Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS | title = Anti-vascular endothelial growth factor for neovascular age-related macular degeneration | journal = The Cochrane Database of Systematic Reviews | volume = 8 | issue = 8 | pages = CD005139 | date = August 2014 | pmid = 25170575 | pmc = 4270425 | doi = 10.1002/14651858.CD005139.pub3 }}</ref> and ].<ref name="Sarwar">{{cite journal | vauthors = Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD | title = Aflibercept for neovascular age-related macular degeneration | journal = The Cochrane Database of Systematic Reviews | volume = 2016 | issue = 2 | pages = CD011346 | date = February 2016 | pmid = 26857947 | pmc = 5030844 | doi = 10.1002/14651858.CD011346.pub2 }}</ref> A 2023 systematic review update found that while ranibizumab and bevacizumab provide similar functional outcomes in ], there is low-certainty evidence suggesting that ranibizumab is more effective in reducing central retinal thickness than bevacizumab.<ref>{{cite journal | vauthors = Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M | title = Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis | journal = The Cochrane Database of Systematic Reviews | volume = 2023 | issue = 6 | pages = CD007419 | date = June 2023 | pmid = 38275741 | pmc = 10294542 | doi = 10.1002/14651858.CD007419.pub7 | collaboration = Cochrane Eyes and Vision Group }}</ref>

Susvimo is a reformulation of ranibizumab suitable for injection via ocular implant.<ref>{{Cite web |title=Susvimo Prescribing Information |url=https://www.gene.com/download/pdf/susvimo_prescribing.pdf |url-status=live |archive-url=https://web.archive.org/web/20240713230751/https://www.gene.com/download/pdf/susvimo_prescribing.pdf |archive-date=13 July 2024 |access-date=23 July 2024 |website=Genentech, Inc.}}</ref> Susvimo was approved for medical use in the United States in October 2021.<ref name="Susvimo FDA label" /><ref>{{cite web |title=Susvimo: FDA-Approved Drugs |url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761197 |url-status=live |archive-url=https://web.archive.org/web/20220803044308/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761197 |archive-date=3 August 2022 |access-date=2 August 2022 |website=U.S. ] (FDA)}}</ref>

== Side effects ==
A 2014 Cochrane review did not find a difference between bevacizumab and ranibizumab in deaths or total severe side effects when used for macular degeneration.<ref name=Moja2014>{{cite journal | vauthors = Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G | veditors = Moja L | title = Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration | journal = The Cochrane Database of Systematic Reviews | volume = 9 | issue = 9 | pages = CD011230 | date = September 2014 | pmid = 25220133 | pmc = 4262120 | doi = 10.1002/14651858.CD011230.pub2 }}</ref> There, however, was not a lot of evidence, and thus this conclusion is not that certain.<ref name=Moja2014/>

Ranibizumab does appear to result in a lower risk of stomach and intestinal problems.<ref name=Moja2014/> It is also associated with a low rate of eye related side effects.<ref>{{cite journal | vauthors = Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK | title = A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard | journal = PLOS ONE | volume = 7 | issue = 8 | pages = e42701 | date = 2012 | pmid = 22880086 | pmc = 3411814 | doi = 10.1371/journal.pone.0042701 | doi-access = free | bibcode = 2012PLoSO...742701S }}</ref>

Serious adverse events related to the injection procedure occurred with an incidence rate of less than 1% and included ], ], and traumatic ]s. Other serious ocular adverse events observed among ranibizumab-treated patients (incidence rate < 1%) included intraocular inflammation and blindness.<ref name="AustriaCodex">{{cite book|title=Austria-Codex| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=de}}{{Page needed|date=July 2011}}</ref>

== Interactions ==
No significant interactions are known.<ref name="Lexicomp"> {{Webarchive|url=https://web.archive.org/web/20210829164205/https://encore.wne.edu/iii/cas/login?service=https%3A%2F%2Fwildpac.wne.edu%3A443%2Fpatroninfo%2F0%2Fredirect%3D%2Fwamvalidate%3Furl%3Dhttp%253A%252F%252F0-online.lexi.com.wildpac.wne.edu%253A80%252Flco%252Faction%252Fdoc%252Fretrieve%252Fdocid%252Fpatch_f%252F518390IIITICKET&scope=0 |date=29 August 2021 }}, Lexi-Drugs. ''Ranibizumab.'' Lexi-Comp, Inc.; 2007.</ref>

==Pharmacology==
Ranibizumab is a ] that inhibits ] by inhibiting ], a mechanism similar to that of ].<ref>{{cite web |url=http://reference.medscape.com/drug/lucentis-ranibizumab-343645#10 |title=ranibizumab |website=medscape |access-date=24 March 2015 |archive-date=30 March 2015 |archive-url=https://web.archive.org/web/20150330025844/http://reference.medscape.com/drug/lucentis-ranibizumab-343645#10 |url-status=live }}</ref>

== Society and culture ==

=== Legal status ===
==== Biosimilars ====
{{see also|Biosimilars}}

Byooviz was approved for medical use in the European Union in August 2021.<ref name="Byooviz EPAR" /><ref>{{cite web | title=Byooviz Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1572.htm | access-date=3 March 2023 | archive-date=3 March 2023 | archive-url=https://web.archive.org/web/20230303201354/https://ec.europa.eu/health/documents/community-register/html/h1572.htm | url-status=live }}</ref>

Ranibizumab-nuna (Byooviz) was approved for medical use in the United States in September 2021.<ref name="Byooviz FDA label" /><ref name="FDA PR 20210920">{{cite press release | title=FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions | website=U.S. ] (FDA) | date=20 September 2021 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions | access-date=20 September 2021 | archive-date=20 September 2021 | archive-url=https://web.archive.org/web/20210920183653/https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions | url-status=live }} {{PD-notice}}</ref>

In India, ] received marketing approval for its biosimilar of Ranibizumab.<ref>{{cite web|title=Lupin receives CDSCO committee approval for marketing ranibizumab|url=http://www.pharmabiz.com/NewsDetails.aspx?aid=139853&sid=1|access-date=24 November 2021|website=www.pharmabiz.com|archive-date=24 November 2021|archive-url=https://web.archive.org/web/20211124102131/http://www.pharmabiz.com/NewsDetails.aspx?aid=139853&sid=1|url-status=live}}</ref>

In June 2022, the ] (CHMP) of the ] (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranivisio, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular edema or choroidal neovascularization, and proliferative diabetic retinopathy.<ref name="Ranivisio: Pending EC decision" /> The applicant for this medicinal product is Midas Pharma GmbH.<ref name="Ranivisio: Pending EC decision">{{cite web | title=Ranivisio: Pending EC decision | website=European Medicines Agency | date=22 June 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ranivisio | access-date=26 June 2022 | archive-date=26 June 2022 | archive-url=https://web.archive.org/web/20220626025455/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ranivisio | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Ranivisio was approved for medical use in the European Union in August 2022.<ref name="Ranivisio EPAR">{{cite web | title=Ranivisio EPAR | website=] (EMA) | date=20 June 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio | access-date=6 October 2022 | archive-date=6 October 2022 | archive-url=https://web.archive.org/web/20221006034343/https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{cite web | title=Ranivisio Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1673.htm | access-date=3 March 2023 | archive-date=3 March 2023 | archive-url=https://web.archive.org/web/20230303201334/https://ec.europa.eu/health/documents/community-register/html/h1673.htm | url-status=live }}</ref>

Ranibizumab-eqrn (Cimerli) was approved for medical use in the United States in August 2022.<ref name="Cimerli FDA label" /><ref>{{cite press release | title=FDA Approves Coherus' Cimerli (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity | publisher=Coherus BioSciences | via=GlobeNewswire News Room | date=2 August 2022 | url=https://www.globenewswire.com/news-release/2022/08/02/2490955/33333/en/FDA-Approves-Coherus-CIMERLI-ranibizumab-eqrn-as-the-First-and-Only-Interchangeable-Biosimilar-to-Lucentis-for-All-Five-Indications-with-12-Months-of-Interchangeability-Exclusivity.html | access-date=2 August 2022 | archive-date=3 August 2022 | archive-url=https://web.archive.org/web/20220803044308/https://www.globenewswire.com/news-release/2022/08/02/2490955/33333/en/FDA-Approves-Coherus-CIMERLI-ranibizumab-eqrn-as-the-First-and-Only-Interchangeable-Biosimilar-to-Lucentis-for-All-Five-Indications-with-12-Months-of-Interchangeability-Exclusivity.html | url-status=live }}</ref>

In September 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ximluci, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization.<ref name="Ximluci: Pending EC decision" /> The applicant for this medicinal product is STADA Arzneimittel AG.<ref name="Ximluci: Pending EC decision">{{cite web | title=Ximluci: Pending EC decision | website=] (EMA) | date=15 September 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ximluci | access-date=18 September 2022 | archive-date=19 September 2022 | archive-url=https://web.archive.org/web/20220919032022/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ximluci | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Ximluci was approved for medical use in the European Union in November 2022.<ref name="Ximluci EPAR">{{cite web | title=Ximluci EPAR | website=European Medicines Agency | date=14 September 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/ximluci | access-date=3 March 2023 | archive-date=13 March 2023 | archive-url=https://web.archive.org/web/20230313235137/https://www.ema.europa.eu/en/medicines/human/EPAR/ximluci | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{cite web | title=Ximluci Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1691.htm | access-date=3 March 2023 | archive-date=17 November 2022 | archive-url=https://web.archive.org/web/20221117235142/https://ec.europa.eu/health/documents/community-register/html/h1691.htm | url-status=live }}</ref>

In November 2023, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rimmyrah, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization.<ref name="Rimmyrah: Pending EC decision" /> The applicant for this medicinal product is QILU PHARMA SPAIN S.L.<ref name="Rimmyrah: Pending EC decision">{{cite web | title=Rimmyrah: Pending EC decision | website=European Medicines Agency | date=10 November 2023 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rimmyrah | access-date=5 December 2023 | archive-date=13 November 2023 | archive-url=https://web.archive.org/web/20231113193718/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/rimmyrah | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> Rimmyrah is a biosimilar medicinal product that is highly similar to the reference product Lucentis (ranibizumab), which was authorized in the EU in January 2007.<ref name="Rimmyrah: Pending EC decision" /> Rimmyrah was approved for medical use in the European Union in January 2024.<ref name="Rimmyrah EPAR">{{cite web | title=Rimmyrah EPAR | website=European Medicines Agency (EMA) | date=5 January 2024 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/rimmyrah | access-date=7 September 2024}}</ref><ref name="Rimmyrah PI">{{cite web | title=Rimmyrah PI | website=Union Register of medicinal products | date=9 January 2024 | url=https://ec.europa.eu/health/documents/community-register/html/h1779.htm | access-date=7 September 2024}}</ref>

In January 2024, Sandoz signed an agreement to acquire ranibizumab-eqrn, the biosimilar version of ranibizumab branded as Cimerli from Coherus BioSciences, Inc. for an upfront cash purchase payment of {{US$|170 million}}.<ref>{{cite web |date=3 August 2022 |title=FDA Approves Ranibizumab-eqrn Biosimilar, Interchangeable with Lucentis |url=https://www.pharmacytimes.com/view/fda-approves-ranibizumab-eqrn-biosimilar-interchangeable-with-lucentis |access-date=22 January 2024 |website=Pharmacy Times |archive-date=19 February 2023 |archive-url=https://web.archive.org/web/20230219010652/https://www.pharmacytimes.com/view/fda-approves-ranibizumab-eqrn-biosimilar-interchangeable-with-lucentis |url-status=live }}</ref><ref>{{cite press release | title=Sandoz announces agreement to acquire Cimerli business from Coherus, strengthening position in US market | url=https://www.sandoz.com/sandoz-announces-agreement-acquire-cimerlir-business-coherus-strengthening-position-us-market/ | access-date=22 January 2024 | website=Sandoz | archive-date=29 January 2024 | archive-url=https://web.archive.org/web/20240129042733/https://www.sandoz.com/sandoz-announces-agreement-acquire-cimerlir-business-coherus-strengthening-position-us-market/ | url-status=live }}</ref><ref>{{cite web |date=22 January 2024 |title=Sandoz: acquisition of ophthalmology biosimilar |url=https://www.marketscreener.com/quote/stock/SANDOZ-GROUP-AG-160016887/news/Sandoz-acquisition-of-ophthalmology-biosimilar-45782186/ |access-date=22 January 2024 |website=MarketScreener |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310055918/https://www.marketscreener.com/quote/stock/SANDOZ-GROUP-AG-160016887/news/Sandoz-acquisition-of-ophthalmology-biosimilar-45782186/ |url-status=live }}</ref>

In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranibizumab Midas, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization.<ref name="Ranibizumab Midas EPAR" /> The applicant for this medicinal product is Midas Pharma GmbH.<ref name="Ranibizumab Midas EPAR" /> Ranibizumab Midas is a biosimilar medicinal product and is a duplicate of Ranivisio.<ref name="Ranibizumab Midas EPAR">{{cite web | title=Ranibizumab Midas EPAR | website=European Medicines Agency | date=25 July 2024 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/ranibizumab-midas | access-date=27 July 2024}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>

=== Economics ===
Its effectiveness is similar to that of ].<ref name=For2014>{{cite journal | vauthors = Formoso G, Marata AM, Magrini N, Bero L | veditors = Tovey D | title = A clearer view of evidence in treating macular degeneration: off-label policies and independent research | journal = The Cochrane Database of Systematic Reviews | volume = 9 | issue = 9 | pages = ED000090 | date = September 2014 | pmid = 25228121 | doi = 10.1002/14651858.ED000090 | doi-access = free | pmc = 10845851 }}</ref><ref name="pmid 22880086">{{cite journal | vauthors = Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK | title = A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard | journal = PLOS ONE | volume = 7 | issue = 8 | pages = e42701 | year = 2012 | pmid = 22880086 | pmc = 3411814 | doi = 10.1371/journal.pone.0042701 | doi-access = free | bibcode = 2012PLoSO...742701S }}</ref> Its rates of side effects also appear similar.<ref name=Moja2014/> However, ranibizumab typically costs $2,000 a dose, while the equivalent dose of bevacizumab typically costs $50.<ref name=WP>{{cite news | url = https://www.washingtonpost.com/business/economy/an-effective-eye-drug-is-available-for-50-but-many-doctors-choose-a-2000-alternative/2013/12/07/1a96628e-55e7-11e3-8304-caf30787c0a9_story.html?hpid=z1
| title = An effective eye drug is available for $50. But many doctors choose a $2,000 alternative. | newspaper = ] | date = 7 December 2013 | vauthors = Whoriskey P, Keating D | access-date = 10 September 2017 | archive-date = 26 January 2021 | archive-url = https://web.archive.org/web/20210126122745/https://www.washingtonpost.com/business/economy/an-effective-eye-drug-is-available-for-50-but-many-doctors-choose-a-2000-alternative/2013/12/07/1a96628e-55e7-11e3-8304-caf30787c0a9_story.html?hpid=z1 | url-status = live }}</ref><ref name="CATT"/><ref>{{cite web | url = http://www.medscape.com/viewarticle/826911_print | title = Switch From Lucentis to Avastin Could Save Medicare $18B | archive-url = https://web.archive.org/web/20210829025723/https://www.medscape.com/viewarticle/826911_print | archive-date=29 August 2021 | vauthors = Henderson D | work = Medscape | date = 17 June 2014 }}</ref><ref name="HealthAffairs">{{cite journal | vauthors = Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J | title = Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period | journal = Health Affairs | volume = 33 | issue = 6 | pages = 931–939 | date = June 2014 | pmid = 24889941 | pmc = 4137040 | doi = 10.1377/hlthaff.2013.0832 }}</ref>

Genentech offered secret rebates to about 300 ophthalmologists in an apparent inducement to get them to use more ranibizumab rather than the less expensive bevacizumab. In 2008, bevacizumab cost Medicare only $20 million for about 480,000 injections, while ranibizumab cost Medicare $537 million for only 337,000 injections.<ref>{{cite news | url = https://www.nytimes.com/2010/11/04/business/04eye.html | title = Genentech Offers Secret Rebates for Eye Drug | work = ] | vauthors = Pollack A | date = 3 November 2010 | access-date = 25 February 2017 | archive-date = 9 November 2020 | archive-url = https://web.archive.org/web/20201109042845/http://www.nytimes.com/2010/11/04/business/04eye.html | url-status = live }}</ref> A small study showed no superior effect of ranibizumab versus bevacizumab in direct comparison.<ref>{{cite journal | vauthors = Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, Houranieh A, Feinberg EB | title = Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial | journal = Eye | volume = 24 | issue = 11 | pages = 1708–1715 | date = November 2010 | pmid = 20885427 | doi = 10.1038/eye.2010.147 | doi-access = free }}</ref> The initial results of the larger Comparison of Age-related Macular Degeneration Treatments Trials (CATT) found that the two drugs "had equivalent effects on visual acuity when administered according to the same schedule;" however, serious adverse events were more common in the bevacizumab arm of the trial.<ref name="CATT">{{cite journal | vauthors = Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ | title = Ranibizumab and bevacizumab for neovascular age-related macular degeneration | journal = The New England Journal of Medicine | volume = 364 | issue = 20 | pages = 1897–1908 | date = May 2011 | pmid = 21526923 | pmc = 3157322 | doi = 10.1056/NEJMoa1102673 }}</ref>

According to a 2012 meta-analysis, the results of several subsequent head-to-head trials found that the two therapies performed equally at restoring visual acuity.<ref name=Jiang2014>{{cite journal | vauthors = Jiang S, Park C, Barner JC | title = Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab | journal = Journal of Clinical Pharmacy and Therapeutics | volume = 39 | issue = 3 | pages = 234–239 | date = June 2014 | pmid = 24635444 | doi = 10.1111/jcpt.12146 | s2cid = 23979022 | doi-access = free }}</ref><ref name=IVAN2013>{{cite journal | vauthors = Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC | title = Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial | journal = Lancet | volume = 382 | issue = 9900 | pages = 1258–1267 | date = October 2013 | pmid = 23870813 | doi = 10.1016/S0140-6736(13)61501-9 | collaboration = IVAN study investigators | doi-access = free }}</ref> A 2012 meta-analysis focused specifically on safety issues concluded that the rates of several adverse events were higher with bevacizumab, although the absolute rates of ocular serious adverse events were low with both therapies: ocular adverse events were about 2.8 times as frequent with bevacizumab than with ranibizumab.<ref name="pmid 22880086" />

== References ==
{{Reflist}}

{{Ocular vascular disorder agents}}
{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}
{{Growth factor receptor modulators}}
{{Portal bar | Medicine}}
{{Authority control}}

]
]
]
]
]
]
]